ConvaTec Group PLC (LON:CTEC) Receives GBX 320.33 Consensus PT from Analysts

Shares of ConvaTec Group PLC (LON:CTEC) have earned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have covered the stock in the last year is GBX 320.33.

CTEC has been the topic of several recent analyst reports. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of ConvaTec Group in a report on Friday, November 14th. UBS Group reaffirmed a “buy” rating and set a GBX 375 price target on shares of ConvaTec Group in a research report on Friday, November 7th. Peel Hunt restated an “add” rating and set a GBX 270 price objective on shares of ConvaTec Group in a research note on Thursday, November 13th. Finally, Berenberg Bank increased their target price on ConvaTec Group from GBX 330 to GBX 340 and gave the stock a “buy” rating in a report on Thursday, January 22nd.

ConvaTec Group Price Performance

CTEC stock opened at GBX 231.40 on Friday. The company has a market capitalization of £4.51 billion, a PE ratio of 21.83, a P/E/G ratio of 0.93 and a beta of 0.64. The company has a quick ratio of 0.96, a current ratio of 2.26 and a debt-to-equity ratio of 85.32. The stock’s 50 day moving average is GBX 234.41 and its two-hundred day moving average is GBX 235.52. ConvaTec Group has a 52-week low of GBX 209.40 and a 52-week high of GBX 311.20.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.